Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial

Jing-Xin Li, Shi-Po Wu, Xi-Ling Guo, Rong Tang, Bao-Ying Huang, Xiao-Qin Chen, Yin Chen, Li-Hua Hou, Jing-Xian Liu, Jin Zhong, Hong-Xing Pan, Feng-Juan Shi, Xiao-Yu Xu, Zhuo-Pei Li, Xiao-Yin Zhang, Lun-Biao Cui, Wen-Jie Tan, Wei Chen, Feng-Cai Zhu, CanSino COVID-19 Study Group, Jing-Xin Li, Shi-Po Wu, Xi-Ling Guo, Rong Tang, Bao-Ying Huang, Xiao-Qin Chen, Yin Chen, Li-Hua Hou, Jing-Xian Liu, Jin Zhong, Hong-Xing Pan, Feng-Juan Shi, Xiao-Yu Xu, Zhuo-Pei Li, Xiao-Yin Zhang, Lun-Biao Cui, Wen-Jie Tan, Wei Chen, Feng-Cai Zhu, Hai-Tao Huang, Jin-Bo Gou, Wei-Xue Si, Xue Wang, Xiao-Long Zhao, Tao Zhu, Jing-Xin Li, Shi-Po Wu, Xi-Ling Guo, Rong Tang, Bao-Ying Huang, Xiao-Qin Chen, Yin Chen, Li-Hua Hou, Jing-Xian Liu, Jin Zhong, Hong-Xing Pan, Feng-Juan Shi, Xiao-Yu Xu, Zhuo-Pei Li, Xiao-Yin Zhang, Lun-Biao Cui, Wen-Jie Tan, Wei Chen, Feng-Cai Zhu, CanSino COVID-19 Study Group, Jing-Xin Li, Shi-Po Wu, Xi-Ling Guo, Rong Tang, Bao-Ying Huang, Xiao-Qin Chen, Yin Chen, Li-Hua Hou, Jing-Xian Liu, Jin Zhong, Hong-Xing Pan, Feng-Juan Shi, Xiao-Yu Xu, Zhuo-Pei Li, Xiao-Yin Zhang, Lun-Biao Cui, Wen-Jie Tan, Wei Chen, Feng-Cai Zhu, Hai-Tao Huang, Jin-Bo Gou, Wei-Xue Si, Xue Wang, Xiao-Long Zhao, Tao Zhu

Abstract

Background: Due to waning immunity and protection against infection with SARS-CoV-2, a third dose of a homologous or heterologous COVID-19 vaccine has been proposed by health agencies for individuals who were previously primed with two doses of an inactivated COVID-19 vaccine.

Methods: We did a randomised, open-label, controlled trial to evaluate the safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in Chinese adults (≥18 years old) who had previously received two doses of an inactivated SARS-CoV-2 vaccine-Sinovac CoronaVac. Eligible participants were randomly assigned (1:1:1) to receive a heterologous booster vaccination with a low dose (1·0 × 1011 viral particles per mL; 0·1 mL; low dose group), or a high dose (1·0 × 1011 viral particles per mL; 0·2 mL; high dose group) aerosolised Ad5-nCoV, or a homologous intramuscular vaccination with CoronaVac (0·5 mL). Only laboratory staff were masked to group assignment. The primary endpoint for safety was the incidence of adverse reactions within 14 days after the booster dose. The primary endpoint for immunogenicity was the geometric mean titres (GMTs) of serum neutralising antibodies (NAbs) against live SARS-CoV-2 virus 14 days after the booster dose. This study was registered with ClinicalTrials.gov, NCT05043259.

Findings: Between Sept 14 and 16, 2021, 420 participants were enrolled: 140 (33%) participants per group. Adverse reactions were reported by 26 (19%) participants in the low dose group and 33 (24%) in the high dose group within 14 days after the booster vaccination, significantly less than the 54 (39%) participants in the CoronaVac group (p<0·0001). The low dose group had a serum NAb GMT of 744·4 (95% CI 520·1-1065·6) and the high dose group had a GMT of 714·1 (479·4-1063·7) 14 days after booster dose, significantly higher than the GMT in the CoronaVac group (78·5 [60·5-101·7]; p<0·0001).

Interpretation: We found that a heterologous booster vaccine with an orally administered aerosolised Ad5-nCoV is safe and highly immunogenic in adults who have previously received two doses of CoronaVac as the primary series vaccination.

Funding: National Natural Science Foundation of China and Jiangsu Provincial Key Research and Development Program.

Copyright © 2022 Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Trial profile *One participant was randomly assigned to receive a booster vaccine with high-dose aerosolised Ad5-nCoV vaccine but was wrongly administrated with a third dose of the CoronaVac. This participant was involved in the intention-to-treat analysis and safety analysis in the originally assigned group.
Figure 2
Figure 2
Solicited and unsolicited adverse reactions that occurred within 14 days after booster vaccination The analysis was based on the safety cohort, which included all randomly assigned participants who received the booster vaccination and had at least one evaluation datapoint available. CV=CoronaVac group. HD=high dose group. LD=low dose group.
Figure 3
Figure 3
Neutralising antibodies against wild-type SARS-CoV-2 before and after a booster vaccination Error bars are 95% CIs. The p values are the results of comparison between the three treatment groups. The WHO reference serum 1000 IU/mL equivalent to live viral neutralising antibody titre of 1:320 against the wild-type SARS-CoV-2. GMTS=geometric mean titre in serum. GMFI=geometric mean fold increase. NAb=neutralising antibody.
Figure 4
Figure 4
SARS-CoV-2 spike-specific cytokine T cells responses before and after receiving a boost vaccination Cytokine T cells were background corrected for unstimulated cells and values lower than 0 were considered negative. Th1:Th2 ratio was calculated by the sum of IFN-γ plus IL-2 cytokine concentrations divided by the sum of IL-13 cytokine concentrations. Error bars are median (IQR). Samples of PBMCs were collected from the first 40 participants in the three treatment groups and included in the analysis. The discrepancies between the numbers of data points presented in the figures and the numbers of participants in the groups are due to the overlapping of the dots. PBMCs=peripheral blood mononuclear cells. TH=T helper cell.

References

    1. WHO Coronavirus disease (COVID-19): Vaccines. 2021.
    1. Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med. 2022;386:340–350.
    1. Zhang W, Davis BD, Chen SS, Sincuir Martinez JM, Plummer JT, Vail E. Emergence of a novel SARS-CoV-2 variant in southern California. JAMA. 2021;325:1324–1326.
    1. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398:2258–2276.
    1. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385:1393–1400.
    1. WHO Interim recommendations for heterologous COVID-19 vaccine schedules. Interim guidance. 2021.
    1. Strategic Advisory Group of Experts Highlights from the meeting of the strategic advisory group of experts (SAGE) on immunization. 2021.
    1. Keskin AU, Bolukcu S, Ciragil P, Topkaya AE. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. J Med Virol. 2022;94:39–41.
    1. Pun Mok CK, Cheng SMS, Chen C, et al. A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac. medRxiv. 2021 doi: 10.1101/2021.11.02.21265843. published online Nov 3.
    1. Li J, Hou L, Guo X, et al. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat Med. 2022;28:401–409.
    1. Wu S, Huang J, Zhang Z, et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis. 2021;21:1654–1664.
    1. Zhu F-C, Li Y-H, Guan X-H, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845–1854.
    1. National Medical Products Administration Notice of the state food and drug administration on issuing the guidelines for the grading standards for adverse events in clinical trials of prophylactic vaccines (2019 No. 102) 2019.
    1. Li J, Hou L, Guo X, et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv. 2021 doi: 10.1101/2021.09.03.21263062. published online Sept 6.
    1. Wang H, Zhang Y, Huang B, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182:713–721.e9.
    1. Zhu F-C, Guan X-H, Li Y-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396:479–488.
    1. Sprangers MC, Lakhai W, Koudstaal W, et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol. 2003;41:5046–5052.
    1. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27:2032–2040.
    1. Kung Y-A, Huang C-G, Huang S-Y, et al. Antibody titers measured by commercial assays are correlated with neutralizing antibody titers calibrated by international standards. medRxiv. 2021 doi: 10.1101/2021.07.16.21260618. published online July 22.
    1. Hsieh S-M, Liu M-C, Chen Y-H, et al. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan. Lancet Respir Med. 2021;9:1396–1406.
    1. Clover Biopharmaceuticals Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest. 2021.
    1. Stuart ASV, Shaw RH, Liu X, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet. 2021;399:36–49.
    1. Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021;398:856–869.
    1. Normark J, Vikström L, Gwon YD, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. N Engl J Med. 2021;385:1049–1051.
    1. Afkhami S, D'Agostino MR, Zhang A, et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell. 2022;185:896–915.e19.
    1. Swarnalekha N, Schreiner D, Litzler LC, et al. T resident helper cells promote humoral responses in the lung. Sci Immunol. 2021;6
    1. Lavelle EC, Ward RW. Mucosal vaccines—fortifying the frontiers. Nat Rev Immunol. 2021 doi: 10.1038/s41577-021-00583-2. published online July 26.
    1. Xu F, Wu S, Yi L, et al. Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques. Emerg Microbes Infect. 2022;11:438–441.
    1. DiPiazza AT, Graham BS, Ruckwardt TJ. T cell immunity to SARS-CoV-2 following natural infection and vaccination. Biochem Biophys Res Commun. 2021;538:211–217.
    1. Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2021;602:671–675.
    1. Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;185:457–466. e4.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner